Literature DB >> 10395073

Arginine vasopressin increases the rate of protein synthesis in isolated perfused adult rat heart via the V1 receptor.

J Fukuzawa1, T Haneda, K Kikuchi.   

Abstract

Arginine vasopressin (AVP) is known to contribute significantly to the pathogenesis of congestive heart failure and hypertension. However, little is known about its effect on the myocardium. The present study was conducted to determine whether AVP directly increases the rate of protein synthesis in isolated, perfused rat heart, and, if so, the mechanism involved. Elevation of the aortic pressure from 60 to 120 mmHg in perfused rat heart accelerated the rate of protein synthesis which was associated with increases in cAMP levels and Ca2+ uptake. AVP (100 microM) increased Ca2+ uptake and accelerated the rate of protein synthesis without a change in cAMP concentration. The latter events were inhibited by OPC-21268 (100 microM), a selective V1 receptor antagonist, or amiloride (100 microM), an inhibitor of the Na+/H+ exchange system. However, increases in cAMP concentrations, Ca2+ uptake, and rates of protein synthesis associated with the elevated aortic pressure were not inhibited by amiloride. Thus, AVP directly increased the rate of protein synthesis via the V1 receptor that is sensitive to amiloride, a mechanism that differs from the cAMP-dependent mechanism that is responsible for the cardiac hypertrophy induced by pressure overload.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10395073     DOI: 10.1023/a:1006980517557

Source DB:  PubMed          Journal:  Mol Cell Biochem        ISSN: 0300-8177            Impact factor:   3.396


  38 in total

1.  Correlations between cardiac protein synthesis rates, intracellular pH and the concentrations of creatine metabolites.

Authors:  P H Sugden; S J Fuller
Journal:  Biochem J       Date:  1991-01-15       Impact factor: 3.857

2.  Stretching cardiac myocytes stimulates protooncogene expression.

Authors:  I Komuro; T Kaida; Y Shibazaki; M Kurabayashi; Y Katoh; E Hoh; F Takaku; Y Yazaki
Journal:  J Biol Chem       Date:  1990-03-05       Impact factor: 5.157

3.  Load responsiveness of protein synthesis in adult mammalian myocardium: role of cardiac deformation linked to sodium influx.

Authors:  R L Kent; J K Hoober; G Cooper
Journal:  Circ Res       Date:  1989-01       Impact factor: 17.367

4.  Protooncogene induction and reprogramming of cardiac gene expression produced by pressure overload.

Authors:  S Izumo; B Nadal-Ginard; V Mahdavi
Journal:  Proc Natl Acad Sci U S A       Date:  1988-01       Impact factor: 11.205

5.  Endothelin-1 induces hypertrophy with enhanced expression of muscle-specific genes in cultured neonatal rat cardiomyocytes.

Authors:  H Ito; Y Hirata; M Hiroe; M Tsujino; S Adachi; T Takamoto; M Nitta; K Taniguchi; F Marumo
Journal:  Circ Res       Date:  1991-07       Impact factor: 17.367

6.  Effects of vasopressin on phosphoinositide hydrolysis and myocardial contractility.

Authors:  M Endoh; M Takanashi; I Norota
Journal:  Eur J Pharmacol       Date:  1992-08-06       Impact factor: 4.432

7.  Regulation of protein synthesis and degradation during in vitro cardiac work.

Authors:  H E Morgan; B H Chua; E O Fuller; D Siehl
Journal:  Am J Physiol       Date:  1980-05

8.  Renin-angiotensin system in stretch-induced hypertrophy of cultured neonatal rat heart cells.

Authors:  S Miyata; T Haneda; J Osaki; K Kikuchi
Journal:  Eur J Pharmacol       Date:  1996-06-20       Impact factor: 4.432

9.  OPC-21268, an orally effective, nonpeptide vasopressin V1 receptor antagonist.

Authors:  Y Yamamura; H Ogawa; T Chihara; K Kondo; T Onogawa; S Nakamura; T Mori; M Tominaga; Y Yabuuchi
Journal:  Science       Date:  1991-04-26       Impact factor: 47.728

10.  Norepinephrine-stimulated hypertrophy of cultured rat myocardial cells is an alpha 1 adrenergic response.

Authors:  P Simpson
Journal:  J Clin Invest       Date:  1983-08       Impact factor: 14.808

View more
  17 in total

1.  Hyperammonaemia in V1a vasopressin receptor knockout mice caused by the promoted proteolysis and reduced intrahepatic blood volume.

Authors:  Masami Hiroyama; Toshinori Aoyagi; Yoko Fujiwara; Sayuri Oshikawa; Atsushi Sanbe; Fumio Endo; Akito Tanoue
Journal:  J Physiol       Date:  2007-03-22       Impact factor: 5.182

2.  Relationship and mechanism of Kv2.1 expression to ADH secretion in rats with heart failure.

Authors:  Jiaxiang Li; Baiyun Tang; Wenbo Zhang; Cuiping Wang; Song Yang; Bao Zhang; Xiuren Gao
Journal:  Am J Transl Res       Date:  2017-08-15       Impact factor: 4.060

3.  Copeptin constitutes a novel biomarker of degenerative aortic stenosis.

Authors:  Katarzyna Mizia-Stec; Bartosz Lasota; Magdalena Mizia; Artur Chmiel; Tomasz Adamczyk; Jerzy Chudek; Zbigniew Gasior
Journal:  Heart Vessels       Date:  2012-11-10       Impact factor: 2.037

Review 4.  Water intake keeps type 2 diabetes away? Focus on copeptin.

Authors:  Giovanna Muscogiuri; Luigi Barrea; Giuseppe Annunziata; Martina Vecchiarini; Francesco Orio; Carolina Di Somma; Annamaria Colao; Silvia Savastano
Journal:  Endocrine       Date:  2018-07-19       Impact factor: 3.633

5.  Copeptin levels associate with cardiovascular events in patients with ESRD and type 2 diabetes mellitus.

Authors:  Wiebke Fenske; Christoph Wanner; Bruno Allolio; Christiane Drechsler; Katja Blouin; Jürgen Lilienthal; Vera Krane
Journal:  J Am Soc Nephrol       Date:  2011-03-17       Impact factor: 10.121

Review 6.  Biomarkers in acute myocardial infarction.

Authors:  Daniel Chan; Leong L Ng
Journal:  BMC Med       Date:  2010-06-07       Impact factor: 8.775

7.  Involvement of ERK and AKT signaling in the growth effect of arginine vasopressin on adult rat cardiac fibroblast and the modulation by simvastatin.

Authors:  Yan-Ping He; Lian-You Zhao; Qiang-Sun Zheng; Shao-Wei Liu; Xiao-Yan Zhao; Xiao-Long Lu; Xiao-Lin Niu; Xia Li
Journal:  Mol Cell Biochem       Date:  2008-06-26       Impact factor: 3.396

Review 8.  Potential of endothelin-1 and vasopressin antagonists for the treatment of congestive heart failure.

Authors:  Navneet S Rehsia; Naranjan S Dhalla
Journal:  Heart Fail Rev       Date:  2010-01       Impact factor: 4.214

9.  An L-RNA-based aquaretic agent that inhibits vasopressin in vivo.

Authors:  Werner G Purschke; Dirk Eulberg; Klaus Buchner; Stefan Vonhoff; Sven Klussmann
Journal:  Proc Natl Acad Sci U S A       Date:  2006-03-17       Impact factor: 11.205

10.  Conivaptan and its role in the treatment of hyponatremia.

Authors:  Jalal K Ghali; Jareer O Farah; Suleiman Daifallah; Hassan A Zabalawi; Hammam D Zmily
Journal:  Drug Des Devel Ther       Date:  2009-12-29       Impact factor: 4.162

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.